HUE033183T2 - Rák kezelésére és/vagy megelõzésére alkalmazható gyógyszerkészítmény - Google Patents

Rák kezelésére és/vagy megelõzésére alkalmazható gyógyszerkészítmény Download PDF

Info

Publication number
HUE033183T2
HUE033183T2 HUE12820775A HUE12820775A HUE033183T2 HU E033183 T2 HUE033183 T2 HU E033183T2 HU E12820775 A HUE12820775 A HU E12820775A HU E12820775 A HUE12820775 A HU E12820775A HU E033183 T2 HUE033183 T2 HU E033183T2
Authority
HU
Hungary
Prior art keywords
ser
cancer
gin
antibody
leu
Prior art date
Application number
HUE12820775A
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Yoshitaka Minamida
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of HUE033183T2 publication Critical patent/HUE033183T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (5)

  1. RÁK KEÜLÉSÉRÉ ÉS/VAGY MEGELŐZÉSÉRE ALKALMAZHATÓ GYÓGYSZlRlÉSZiTMiRY Szabadalmi igénypontok
    1, Antitest vagy fragrnense, amely immunológiai reaktivitással rendelkezik egy GÁRRSN4 fehérje leié, az antitest vagy fragrnense tartalmaz olyan nehézlánc variábilis régiót, amely tartalmazza a SEQ ID NO: 5, 6 és 7 szerinti kompíemerkariíás-meghatározó régiókat, és olyan könnyüíánc variábilis régiót, amely tartalmazza a SEQ ID NCk 9. 10 és 11 szerinti komplementaritás-meghatározó régiókat. 2. A 1. igénypont szerinti antitest vagy fragrnense, ahol az antitest humán antitest, humanizált antitest, kiméri antitest, égyláncü antitest vagy myltiépeoifikas antitest.
  2. 3. Az 1. vagy 2. igénypont szerinti antitest vagy fragrnense, aho! az antitest vagy fragrnense temoreflenes ágenssel van konjugáiva.
  3. 4, Az előző igénypontok bármelyike szerinti antitest vagy fragrnense rák kezelésére és/vagy megelőzésére szolgáié eljárásban történő alkalmazásra. S* Az antitest vagy fragrnense alkalmazásra a A igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirigyrák, vastaghélrák, tüdőrák, agyturnor. gyomorrák, méhnyakrák, petefészekrák, prosztatarák, hágyhőiyegrák: nyélőcsérál, leukémia:, iímíórna, fibroszarkima, masztoc>f.óma vagy meianőma. $* Gyógyászati készítmény, amely hatóanyagként tartalmaz az i-$. igénypontok bármelyike szerinti antitestet vagy fragmensÉi f, A 8. igénypont szerinti gyógyászati készítmény rak kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra,
  4. 8, A gyógyászati készítmény aikalmazásra a 7. Igénypont szerint, ahol a rák mellrák, veserák, hasnyálmirígyrák, vastagbélrák, tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, hügyhélysgrák, nyeiőcsőrák:, leukémia, iimfims, fbroszarkóma, masztocitóma vagy melanoma. tk Gyógyászati kombináció, amely íattalrnaz a i. igénypont szerinti gyógyászati készítményt, valamint tumorellenes ágenst tartalmazó gyógyászati készítményt, ΙΟ, A 9. igénypont szerinti gyógyászati kombináció rák kezelésére és/vagy megelőzésére szolgáló eljárásban tőiMnő álkalmazásra,
  5. 11, A gyógyászati kombináció alkalmazásra a 10. Igénypont szerint, ahol a rák mellrák, vasárak, kaihyálmirigyrákv vastagbélrák. tüdőrák, agytumor, gyomorrák, méhnyakrák, petefészekrák, prosztatarák, húgyhőlyagrák, nyelőcsörák, leukémia, imfőma, fíbroszarkóma, masztocitóma vagy méla néma . 12< DNS, amely kódol az 1, vagy g igénypont szerinti antitestet vagy íragmensét.
HUE12820775A 2011-08-04 2012-08-03 Rák kezelésére és/vagy megelõzésére alkalmazható gyógyszerkészítmény HUE033183T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011171303 2011-08-04

Publications (1)

Publication Number Publication Date
HUE033183T2 true HUE033183T2 (hu) 2017-11-28

Family

ID=47629397

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12820775A HUE033183T2 (hu) 2011-08-04 2012-08-03 Rák kezelésére és/vagy megelõzésére alkalmazható gyógyszerkészítmény

Country Status (16)

Country Link
US (1) US9180188B2 (hu)
EP (1) EP2740798B1 (hu)
JP (1) JP6065592B2 (hu)
KR (1) KR101968499B1 (hu)
CN (1) CN103717737B (hu)
AU (1) AU2012290946B2 (hu)
BR (1) BR112014002614B1 (hu)
CA (1) CA2844030C (hu)
DK (1) DK2740798T3 (hu)
ES (1) ES2618026T3 (hu)
HU (1) HUE033183T2 (hu)
MX (1) MX348581B (hu)
PL (1) PL2740798T3 (hu)
PT (1) PT2740798T (hu)
RU (1) RU2595400C2 (hu)
WO (1) WO2013018883A1 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
PT2532743E (pt) * 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
HUE030130T2 (hu) * 2011-08-04 2017-04-28 Toray Industries Gyógyászati készítmény hasnyálmirigyrák kezelésére és/vagy megelõzésére
DK2741085T3 (en) * 2011-08-04 2017-06-19 Toray Industries Method for detecting pancreatic cancer
HUE034736T2 (hu) 2012-02-21 2018-02-28 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
RU2640245C2 (ru) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
PT2876446T (pt) 2012-07-19 2019-03-25 Toray Industries Método para deteção de cancro
MX358772B (es) 2012-07-19 2018-09-04 Toray Industries Metodo para detectar cancer.
PL3031826T3 (pl) 2013-08-09 2019-03-29 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
MX2019004779A (es) 2016-10-28 2019-08-12 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
EP3601365A4 (en) * 2017-03-29 2021-01-13 Agency for Science, Technology and Research ANTI-OLIGOSACCHARIDE ANTIBODIES
MX2020009862A (es) 2018-03-30 2020-10-08 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020252294A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
MX2022004875A (es) 2019-10-25 2022-06-17 Bolt Biotherapeutics Inc Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
EP4119158A4 (en) 2020-03-12 2024-05-08 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
KR20220153621A (ko) 2020-03-12 2022-11-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
JPWO2021182573A1 (hu) 2020-03-12 2021-09-16
WO2021182572A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
JPWO2021182574A1 (hu) 2020-03-12 2021-09-16
EP4146282A1 (en) 2020-05-08 2023-03-15 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CN116234586A (zh) 2020-08-13 2023-06-06 博尔特生物治疗药物有限公司 吡唑并氮呯免疫缀合物及其用途
EP4360649A1 (en) 2021-06-23 2024-05-01 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240024074A (ko) 2021-06-23 2024-02-23 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2022320304A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2023008461A1 (hu) 2021-07-27 2023-02-02
WO2023008459A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
CN118119409A (zh) 2021-09-03 2024-05-31 东丽株式会社 癌的治疗和/或预防用药物组合物
EP4422697A1 (en) 2021-10-29 2024-09-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2001032910A2 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
IL138801A0 (en) 1998-04-03 2001-10-31 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor and process for the preparation thereof
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NZ509178A (en) 1998-07-14 2004-04-30 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2000060077A2 (en) 1999-04-02 2000-10-12 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CZ20023567A3 (cs) 2000-03-29 2003-11-12 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
KR100583331B1 (ko) 2001-05-11 2006-05-26 기린 비루 가부시키가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
CA2524173A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
WO2005116076A2 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
ES2387809T3 (es) 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
PL1730191T3 (pl) 2004-03-30 2011-12-30 Glaxo Group Ltd Immunoglobuliny wiążące hosm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
EP1849002A4 (en) 2005-02-18 2008-08-20 Childrens Medical Center CYR61 AS A BIOMARKER FOR THE DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN
MX2007011024A (es) 2005-03-11 2009-11-23 Vermillion Inc Biomarcadores para cancer de ovario y cancer de endometrio: hepcidin.
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
WO2008073162A2 (en) 2006-08-17 2008-06-19 Cell Signaling Technology, Inc. Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
PL2322221T3 (pl) * 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
KR20160127146A (ko) * 2008-08-05 2016-11-02 도레이 카부시키가이샤 면역 유도제
SG178348A1 (en) 2009-08-19 2012-03-29 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
KR101545914B1 (ko) 2009-09-22 2015-08-20 프로바이오겐 아게 특수화된 글리칸 구조를 함유하는 분자의 생산 방법
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
EP2532364B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
AU2011211684B2 (en) 2010-02-04 2014-09-25 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN109925511B (zh) * 2010-02-04 2024-03-19 东丽株式会社 用于癌的治疗和/或预防的药物
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2011096533A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
US20110206976A1 (en) 2010-02-19 2011-08-25 Kyung-Mo Yoo Electrode assembly and secondary battery using the same
JP2013012815A (ja) 2011-06-28 2013-01-17 Sony Corp 画像処理装置及び画像処理方法
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
DK2741085T3 (en) 2011-08-04 2017-06-19 Toray Industries Method for detecting pancreatic cancer
RU2640245C2 (ru) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer

Also Published As

Publication number Publication date
DK2740798T3 (en) 2017-03-06
US9180188B2 (en) 2015-11-10
CA2844030A1 (en) 2013-02-07
EP2740798A1 (en) 2014-06-11
EP2740798A4 (en) 2015-04-15
AU2012290946A1 (en) 2014-03-20
BR112014002614A2 (pt) 2018-02-20
PT2740798T (pt) 2017-03-13
CN103717737A (zh) 2014-04-09
RU2595400C2 (ru) 2016-08-27
KR101968499B1 (ko) 2019-04-12
CN103717737B (zh) 2015-06-10
CA2844030C (en) 2019-09-03
MX2014001374A (es) 2014-03-21
WO2013018883A1 (ja) 2013-02-07
AU2012290946B2 (en) 2016-04-21
MX348581B (es) 2017-06-20
PL2740798T3 (pl) 2017-07-31
ES2618026T3 (es) 2017-06-20
BR112014002614B1 (pt) 2022-09-20
RU2014108049A (ru) 2015-09-10
JPWO2013018883A1 (ja) 2015-03-05
JP6065592B2 (ja) 2017-01-25
KR20140054182A (ko) 2014-05-08
US20140193434A1 (en) 2014-07-10
EP2740798B1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
DK2740798T3 (en) Drug composition for cancer treatment and / or prevention
DK2740794T3 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
DK2740795T3 (en) Pharmaceutical composition for the treatment and / or prevention of cancer
DK2740793T3 (en) PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
DK2818483T3 (en) Medical composition for the treatment and / or prevention of cancer
AU2013223143B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer
CA2864999C (en) Pharmaceutical composition for treatment and/or prevention of cancer
DK2740796T3 (en) Pharmaceutical composition for the treatment and / or prevention of cancer